SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fonseca, R. Articles by Dewald, G. W. Search for Related Content PubMed PubMed Citation Articles by Fonseca, R. Articles by Dewald, G. W. Related Collections Neoplasia Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2002, Vol. 100, No. 4, pp. 1417-1424 NEOPLASIA Genomic abnormalities in monoclonal gammopathy of undetermined significance Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S. Vincent Rajkumar, James D. Hoyer, John A. Lust, Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, and Gordon W. Dewald From the Division of Hematology and Department of Internal Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Translocations involving immunoglobulin (Ig) loci and chromosome 13 monosomy (13) are frequent cytogenetic findings in multiple myeloma (MM). Similar chromosomal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS), but their prevalence and significance remain uncertain. Bone marrow from 72 patients with MGUS (n = 62) and smoldering MM (n = 10) was evaluated for translocations between the Ig heavy chain (IgH) and chromosomes 4, 11, and 16, translocations involving Ig light chain-lambda (IgL-, and 13. Fluorescence in situ hybridization (FISH) analysis was done on clonal plasma cells (PCs) detected by immunofluorescence (cIg-FISH) of the cytoplasmic light chain. We also studied cells for cyclin D1 and FGFR3 up-regulation by immunohistochemistry and immunofluorescence, respectively. Twenty-seven (46%) of 59 patients had IgH translocations, and 4 (11%) of 37 had an IgL- translocation. A t(11;14)(q13;q32) was found in 15 (25%) of 59 patients, a t(4;14)(p16.3;q32) in 9% of patients, and a t(14;16)(q32;q23) in 5% of patients. All patients with t(4;14)(p16.3;q32) tested (n = 3) had intense cytoplasmic fluorescence with an anti-FGFR3 antibody. PC nuclear staining of cyclin D1 was only observed in patients with t(11;14)(q13;q32); 13 was detected in the clonal PCs in 50% of patients. The percentage of abnormal PCs varied with any given abnormality. No obvious clinical or biologic correlations were associated with these chromosome abnormalities. Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH Gienke R. Boersma-Vreugdenhil, Ton Peeters, and Bert J. E. G. Bast Blood 2003 101: 1653. [Full Text] [PDF] This article has been cited by other articles: L. Chiecchio, G. P. Dagrada, A. H. Ibrahim, E. Dachs Cabanas, R. K.M. Protheroe, D. M. Stockley, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context Haematologica, December 1, 2009; 94(12): 1708 - 1713. [Abstract] [Full Text] [PDF] S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood, October 8, 2009; 114(15): 3276 - 3284. [Abstract] [Full Text] [PDF] A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al. Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma J. Clin. Oncol., September 1, 2009; 27(25): 4197 - 4203. [Abstract] [Full Text] [PDF] L. Chiecchio, G. P. Dagrada, R. K.M. Protheroe, D. M. Stockley, A. G. Smith, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, and on behalf of the UK Myeloma Forum Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case Haematologica, July 1, 2009; 94(7): 1024 - 1028. [Abstract] [Full Text] [PDF] B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl A monoclonal gammopathy precedes multiple myeloma in most patients Blood, May 28, 2009; 113(22): 5418 - 5422. [Abstract] [Full Text] [PDF] A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica, March 1, 2009; 94(3): 380 - 386. [Abstract] [Full Text] [PDF] J Yeung and H Chang Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma J. Clin. Pathol., July 1, 2008; 61(7): 832 - 836. [Abstract] [Full Text] [PDF] A. Dib, A. Gabrea, O. K. Glebov, P. L. Bergsagel, and W. M. Kuehl Characterization of MYC Translocations in Multiple Myeloma Cell Lines J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 25 - 31. [Abstract] [Full Text] [PDF] O. Landgren, L. R. Goldin, N. E. Caporaso, R. A. Kyle, and S. V. Rajkumar Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance-reply-I Mayo Clin. Proc., May 1, 2008; 83(5): 602 - 603. [Full Text] [PDF] T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF] M. Martin-Ayuso, J. Almeida, M. Perez-Andres, R. Cuello, J. Galende, M. I. Gonzalez-Fraile, G. Martin-Nunez, F. Ortega, M. J. Rodriguez, J. F. San Miguel, et al. Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired Oncologist, January 1, 2008; 13(1): 82 - 92. [Abstract] [Full Text] [PDF] N. C. Munshi Monoclonal Gammopathy of Undetermined Significance: Genetic vs Environmental Etiologies Mayo Clin. Proc., December 1, 2007; 82(12): 1457 - 1459. [Full Text] [PDF] M. Brousseau, X. Leleu, J. Gerard, T. Gastinne, A. Godon, F. Genevieve, M. Dib, J.-L. Lai, T. Facon, M. Zandecki, et al. Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients Clin. Cancer Res., October 15, 2007; 13(20): 6026 - 6031. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] H. Tatetsu, S. Ueno, H. Hata, Y. Yamada, M. Takeya, H. Mitsuya, D. G. Tenen, and Y. Okuno Down-regulation of PU.1 by Methylation of Distal Regulatory Elements and the Promoter Is Required for Myeloma Cell Growth Cancer Res., June 1, 2007; 67(11): 5328 - 5336. [Abstract] [Full Text] [PDF] S. H. Cheng, M. H. L. Ng, K. M. Lau, H. S. Y. Liu, J. C. W. Chan, A. B. Y. Hui, K. W. Lo, H. Jiang, J. Hou, R. W. Chu, et al. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4 Blood, March 1, 2007; 109(5): 2089 - 2099. [Abstract] [Full Text] [PDF] F. Zhan, B. Barlogie, V. Arzoumanian, Y. Huang, D. R. Williams, K. Hollmig, M. Pineda-Roman, G. Tricot, F. van Rhee, M. Zangari, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis Blood, February 15, 2007; 109(4): 1692 - 1700. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF] F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF] J. R. Cook, M. Hartke, J. Pettay, and R. R. Tubbs Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence J. Mol. Diagn., September 1, 2006; 8(4): 459 - 465. [Abstract] [Full Text] [PDF] B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma Blood, September 1, 2006; 108(5): 1733 - 1743. [Abstract] [Full Text] [PDF] I. Hanamura, J. P. Stewart, Y. Huang, F. Zhan, M. Santra, J. R. Sawyer, K. Hollmig, M. Zangarri, M. Pineda-Roman, F. van Rhee, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation Blood, September 1, 2006; 108(5): 1724 - 1732. [Abstract] [Full Text] [PDF] M. A. Gertz, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, M. R. Litzow, K. J. Henderson, S. A. Van Wier, G. J. Ahmann, and R. Fonseca Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood, October 15, 2005; 106(8): 2837 - 2840. [Abstract] [Full Text] [PDF] S. V. Rajkumar and R. A. Kyle Multiple Myeloma: Diagnosis and Treatment Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382. [Abstract] [PDF] W. J. Chng, S. A. Van Wier, G. J. Ahmann, J. M. Winkler, S. M. Jalal, P. L. Bergsagel, M. Chesi, M. C. Trendle, M. M. Oken, E. Blood, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS Blood, September 15, 2005; 106(6): 2156 - 2161. [Abstract] [Full Text] [PDF] P. L. Bergsagel and W. M. Kuehl Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6333 - 6338. [Abstract] [Full Text] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF] S. Girlanda, C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al. MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes Cancer Res., August 15, 2005; 65(16): 7502 - 7508. [Abstract] [Full Text] [PDF] R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis Blood, January 15, 2005; 105(2): 794 - 803. [Abstract] [Full Text] [PDF] S. V. Rajkumar MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management Hematology, January 1, 2005; 2005(1): 340 - 345. [Abstract] [Full Text] [PDF] W. M. Kuehl and P. L. Bergsagel Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma Hematology, January 1, 2005; 2005(1): 346 - 352. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report Cancer Res., February 15, 2004; 64(4): 1546 - 1558. [Abstract] [Full Text] [PDF] F. E. Davies, A. M. Dring, C. Li, A. C. Rawstron, M. A. Shammas, S. M. O'Connor, J. A.L. Fenton, T. Hideshima, D. Chauhan, I. T. Tai, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis Blood, December 15, 2003; 102(13): 4504 - 4511. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, J. Krasovsky, K. Osman, and M. D. Geller Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy J. Exp. Med., December 1, 2003; 198(11): 1753 - 1757. [Abstract] [Full Text] [PDF] R. A. Kyle, T. M. Therneau, S. V. Rajkumar, E. D. Remstein, J. R. Offord, D. R. Larson, M. F. Plevak, and L. J. Melton III Long-term follow-up of IgM monoclonal gammopathy of undetermined significance Blood, November 15, 2003; 102(10): 3759 - 3764. [Abstract] [Full Text] [PDF] R. Fonseca, C. S. Debes-Marun, E. B. Picken, G. W. Dewald, S. C. Bryant, J. M. Winkler, E. Blood, M. M. Oken, R. Santana-Davila, N. Gonzalez-Paz, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood, October 1, 2003; 102(7): 2562 - 2567. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S.-I. Fujii, K. M. Dhodapkar, and J. Krasovsky A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma J. Exp. Med., June 16, 2003; 197(12): 1667 - 1676. [Abstract] [Full Text] [PDF] R. Fonseca, E. Blood, M. Rue, D. Harrington, M. M. Oken, R. A. Kyle, G. W. Dewald, B. Van Ness, S. A. Van Wier, K. J. Henderson, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood, June 1, 2003; 101(11): 4569 - 4575. [Abstract] [Full Text] [PDF] M. Santra, F. Zhan, E. Tian, B. Barlogie, and J. Shaughnessy Jr A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript Blood, March 15, 2003; 101(6): 2374 - 2376. [Abstract] [Full Text] [PDF] G. R. Boersma-Vreugdenhil, T. Peeters, and B. J. E. G. Bast Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH Blood, February 15, 2003; 101(4): 1653 - 1653. [Full Text] [PDF] J. J. Keats, T. Reiman, C. A. Maxwell, B. J. Taylor, L. M. Larratt, M. J. Mant, A. R. Belch, and L. M. Pilarski In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood, February 15, 2003; 101(4): 1520 - 1529. [Abstract] [Full Text] [PDF] S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020